临床前CRO市场－全球产业规模、份额、趋势、机会及预测（依服务、模式类型、最终用途产业、地区及竞争格局划分，2021-2031年）

全球临床前 CRO 市场预计将从 2025 年的 66.7 亿美元成长到 2031 年的 111.3 亿美元，复合年增长率为 8.91%。

该领域包括提供关键早期研究服务的第三方供应商，例如毒性评估、生物分析和药物代谢评价，以检验人体临床试验前候选疗法的安全性和有效性。主要成长要素是药物发现过程日益复杂，以及生物製药公司在最大限度降低财务风险的同时加快研发进程的需求不断增长。因此，申办方经常将这些关键活动外包，以利用内部维护成本过高的专业知识和基础设施。

儘管市场需求强劲，但由于国际机构实施的严格监管标准，市场面临许多挑战。这些标准通常需要耗费巨资执行合规通讯协定，并可能延误计划完成。然而，在推动外包业务发展的巨额创新投资的驱动下，该产业依然蓬勃发展。欧洲製药工业协会联合会 (EFPIA) 报告称，欧洲製药业预计将在 2024 年投入约 550 亿欧元用于研发。持续的研发投入凸显了受託研究机构(CRO) 在加速新型疗法开发方面所扮演的重要角色。

市场驱动因素

生物製药公司为将固定内部成本转化为可变外部支出，日益增长的策略性研发外包趋势是全球临床前CRO市场的主要驱动力。随着药物研发资本密集度的提高，主要企业正在缩减内部基础设施，并与CRO建立一体化合作伙伴关係，以降低财务风险并获得专业平台的使用权。服务供应商从大型企业客户获得的收入不断成长，也印证了这项转变。例如，药明康德发布的《2024年年度报告》显示，2024年全球前20大製药公司的营收将达到166.4亿元人民币，年增24.1%。

同时，生物製药和先进疗法研发管线的快速成长正在改变市场需求。这些先进治疗方法需要一些特殊的毒理学和生物分析技术，而这些技术很难在企业内部获得。基因编辑和细胞疗法的行业研究正在蓬勃发展，这需要专业的合约研究组织（CRO）提供先进的测试模型。美国基因与细胞治疗学会（ASGCT）在其2024年6月年会总结中报告称，摘要数量同比增长12%，约2000篇，这表明该领域正在扩张。这些持续的研究正在产生实际的市场成果。 2025年2月，Labcorp宣布其早期开发部门2024年第四季的营收成长了12.3%，凸显了早期外包业务的强劲发展势头。

市场挑战

严格的监管合规标准造成了复杂的商业环境，并直接阻碍了全球临床前CRO市场的扩张。为了满足FDA和EMA等机构制定的安全性和有效性标准，合约研究组织（CRO）必须维持高成本且严格的品质保证体系，并进行全面的毒理学研究。这些强制性的合规程序显着增加了计划完成所需的时间和资金，从而在开发平臺中造成了瓶颈。 CRO必须将大量资源投入监管文件和通讯协定检验中，而不是扩大生产能力，这减缓了候选药物的研发速度，并限制了整体市场容量。

这些合规要求带来的财务负担进一步限制了市场成长，因为它们会耗尽原本可用于支援更多外包协议的研发预算。据美国药品研究与製造商协会（PhRMA）称，其成员公司将在2024年投入约152亿美元用于非人体测试和非临床试验活动。这笔巨额支出凸显了监管要求消耗了药物研发资金的很大一部分。因此，申办方在新专案申请方面面临很高的准入门槛，导致研发管线整合加剧，以及外包给非临床服务供应商的早期研究数量下降。

市场趋势

人工智慧 (AI) 和机器学习在预测毒理学领域的应用正在改变这一领域，它将早期安全性评估从传统的体内模型转向先进的运算平台。服务供应商正在利用人工智慧驱动的演算法处理大量资料集，从而能够及早发现毒性风险，并显着降低药物候选物在进行成本高昂的动物试验之前被淘汰的比例。主要产业参与者投入大规模支持这项技术变革，他们希望检验能够更准确预测不利事件的In Silico方法。正如 2025 年 10 月《全球创投》杂誌的一篇报导《赛诺菲创投注资 6.25 亿美元聚焦人工智慧》所述，赛诺菲已向其企业创投基金注资 6.25 亿美元，以扩大其对人工智慧驱动的药物发现技术的关注，这标誌着其资本向预测工具的重大重新配置。

同时，透过策略性併购加速市场整合正在重塑竞争格局，各公司都在寻求建构整合化的端到端服务平台。为了解决专业服务分散的问题，市场参与企业正积极寻求併购，将湿实验室能力与先进的计算技术相结合，以提供优化整个药物研发生命週期的综合解决方案。这一趋势在「生物科技」公司与传统合约研究模式的合作中尤为明显，双方携手构建了能够无缝衔接从靶点识别到先导药物最适化的整合式药物研发引擎。例如，Recursion Pharmaceuticals在其2025年2月发布的2024年度报告中宣布，已完成对Exscientia的收购，交易金额为6.301亿美元。此次交易建立了一个垂直整合的平台，将生物工程和自动化化学相结合，服务于製药业。

目录

第一章概述

第二章调查方法

第三章执行摘要

第四章：客户评价

第五章：全球临床前CRO市场展望

• 市场规模及预测
  • 按金额
• 市占率及预测
  • 按服务项目（生物分析/DMPK 测试、毒性测试、化合物管理、化学、安全药理学、其他）
  • 依模型类型（病患来源类器官（PDO）模型、病患来源异种移植模型）
  • 依最终用户产业划分（生物製药公司、政府/学术机构、医疗设备公司）
  • 按地区
  • 按公司（2025 年）
• 市场地图

6. 北美临床前CRO市场展望

• 市场规模及预测
• 市占率及预测
• 北美洲：国家分析
  • 我们
  • 加拿大
  • 墨西哥

7. 欧洲临床前CRO市场展望

• 市场规模及预测
• 市占率及预测
• 欧洲：国家分析
  • 德国
  • 法国
  • 英国
  • 义大利
  • 西班牙

8. 亚太地区临床前CRO市场展望

• 市场规模及预测
• 市占率及预测
• 亚太地区：国家分析
  • 中国
  • 印度
  • 日本
  • 韩国
  • 澳洲

9. 中东和非洲临床前CRO市场展望

• 市场规模及预测
• 市占率及预测
• 中东和非洲：国家分析
  • 沙乌地阿拉伯
  • 阿拉伯聯合大公国
  • 南非

第十章：南美临床前CRO市场展望

• 市场规模及预测
• 市占率及预测
• 南美洲：国家分析
  • 巴西
  • 哥伦比亚
  • 阿根廷

第十一章 市场动态

• 司机
• 任务

第十二章 市场趋势与发展

• 併购
• 产品发布
• 最新进展

第十三章 全球临床前CRO市场：SWOT分析

第十四章：波特五力分析

• 产业竞争
• 新进入者的可能性
• 供应商电力
• 顾客权力
• 替代品的威胁

第十五章 竞争格局

• Eurofins Scientific SE
• PRA Health Sciences, Inc.
• Medpace, Inc.
• Charles River Laboratories International, Inc.
• PPD, Inc.
• SGA SA
• Intertek Group Plc
• LABCORP Inc.
• Crown Bioscience Inc

第十六章 策略建议

第十七章：关于研究公司及免责声明

The Global Preclinical CRO Market is projected to expand from USD 6.67 Billion in 2025 to USD 11.13 Billion by 2031, registering a CAGR of 8.91%. This sector encompasses third-party entities providing essential early-stage research services, including toxicology assessments, bioanalysis, and drug metabolism evaluations, designed to verify the safety and efficacy of therapeutic candidates prior to human trials. Key growth drivers include the increasing intricacy of drug discovery and the strategic need for biopharmaceutical firms to expedite development while minimizing financial exposure. Consequently, sponsors are frequently outsourcing these vital tasks to utilize specialized expertise and infrastructure that would be economically burdensome to sustain in-house.

Despite strong demand, the market encounters significant hurdles due to rigorous regulatory compliance standards mandated by international agencies, which often require expensive adherence protocols and can retard project completion. Nevertheless, the industry continues to thrive on substantial innovation investments that drive the outsourcing pipeline. As reported by the European Federation of Pharmaceutical Industries and Associations, the pharmaceutical sector allocated an estimated €55,000 million to R&D in Europe in 2024. This continuous capital investment in research and development highlights the critical function of contract research organizations in facilitating the progression of new therapeutics.

Market Driver

The growing trend of strategic R&D outsourcing by biopharmaceutical firms serves as a major driver for the Global Preclinical CRO Market, motivated by the need to transform fixed internal costs into variable external expenditures. With drug discovery becoming more capital-intensive, leading pharmaceutical companies are reducing internal infrastructure to form integrated alliances with contract research organizations, thereby mitigating financial risks and gaining access to specialized platforms. This shift is demonstrated by the rising revenues service providers are securing from large-cap clients; for example, WuXi AppTec's '2024 Annual Report' noted that revenue from the top 20 global pharmaceutical companies hit RMB 16.64 billion in 2024, marking a 24.1% year-over-year rise.

Concurrently, the surge in biologics and advanced therapy pipelines is altering demand, as these sophisticated modalities necessitate niche toxicology and bioanalysis skills often unavailable internally. The industry is seeing increased research into gene editing and cell-based therapies, which requires the advanced testing models offered by specialized CROs. The American Society of Gene & Cell Therapy reported in its June 2024 '2024 Annual Meeting' summary that the field's expansion was evidenced by nearly 2,000 abstract presentations, a 12% increase from the previous year. This ongoing research activity is yielding concrete market results, as Labcorp announced in February 2025 that its Early Development segment revenue increased by 12.3% in the fourth quarter of 2024, highlighting the strong momentum in early-stage outsourcing.

Market Challenge

Stringent regulatory compliance standards create a complex operational landscape that directly impedes the expansion of the Global Preclinical CRO Market. To satisfy safety and efficacy benchmarks established by bodies such as the FDA and EMA, contract research organizations are required to uphold costly, exacting quality assurance systems and perform comprehensive toxicology testing. These compulsory adherence steps substantially raise the time and capital needed for project completion, causing bottlenecks in the development pipeline. Because CROs must allocate significant resources to regulatory documentation and protocol validation instead of capacity growth, the speed at which they process new drug candidates slows, thereby restricting total market throughput.

The financial weight of these compliance mandates further limits market growth by depleting R&D budgets that might otherwise support additional outsourcing agreements. According to the Pharmaceutical Research and Manufacturers of America (PhRMA), member companies directed roughly $15.2 billion specifically toward pre-human and preclinical testing activities in 2024. This significant outlay underscores how regulatory requirements consume a large portion of discovery capital. As a result, sponsors encounter elevated entry barriers for new programs, frequently resulting in pipeline consolidation and a decrease in the number of early-stage studies assigned to preclinical service providers.

Market Trends

The incorporation of Artificial Intelligence and Machine Learning for Predictive Toxicology is transforming the sector by moving early-stage safety assessments from solely in vivo models to sophisticated computational platforms. Service providers are increasingly utilizing AI-driven algorithms to process massive datasets, enabling the early detection of toxicity risks and significantly lowering the attrition rate of drug candidates prior to expensive animal trials. This technological shift is supported by major capital investments from key industry players seeking to validate in silico methods capable of more accurately predicting adverse events. As noted by Global Venturing in October 2025, in the article 'Sanofi Ventures bets on AI with $625m cash influx', Sanofi injected $625 million into its corporate venture fund expressly to target and expand AI-driven drug discovery technologies, indicating a substantial reallocation of capital toward these predictive tools.

Simultaneously, the acceleration of market consolidation through strategic mergers and acquisitions is reshaping the competitive environment as entities aim to build integrated, end-to-end service platforms. To address the fragmentation of specialized services, market participants are actively engaging in M&A to merge wet-lab capacities with advanced computational technologies, delivering comprehensive solutions that optimize the drug development lifecycle. This trend is illustrated by the union of "TechBio" firms and conventional contract research models to form unified discovery engines that facilitate a smooth transition from target identification to lead optimization for partners. For instance, Recursion Pharmaceuticals stated in its February 2025 '2024 Annual Report' that it finalized the acquisition of Exscientia for $630.1 million, establishing a vertically integrated platform that combines biological engineering with automated chemistry to serve the pharmaceutical industry.

Key Market Players

• Eurofins Scientific SE
• PRA Health Sciences, Inc.
• Medpace, Inc.
• Charles River Laboratories International, Inc.
• PPD, Inc.
• SGA SA
• Intertek Group Plc
• LABCORP Inc.
• Crown Bioscience Inc

Report Scope

In this report, the Global Preclinical CRO Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Preclinical CRO Market, By Service

• Bioanalysis and DMPK studies
• Toxicology Testing
• Compound Management
• Chemistry
• Safety Pharmacology
• Others

Preclinical CRO Market, By Model Type

• Patient Derived Organoid (PDO) Model
• Patient derived xenograft model

Preclinical CRO Market, By End-Use Industry

• Biopharmaceutical Companies
• Government and Academic Institutes
• Medical Device Companies

Preclinical CRO Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Preclinical CRO Market.

Available Customizations:

Global Preclinical CRO Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Preclinical CRO Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Service (Bioanalysis and DMPK studies, Toxicology Testing, Compound Management, Chemistry, Safety Pharmacology, Others)
  • 5.2.2. By Model Type (Patient Derived Organoid (PDO) Model, Patient derived xenograft model)
  • 5.2.3. By End-Use Industry (Biopharmaceutical Companies, Government and Academic Institutes, Medical Device Companies)
  • 5.2.4. By Region
  • 5.2.5. By Company (2025)
• 5.3. Market Map

6. North America Preclinical CRO Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Service
  • 6.2.2. By Model Type
  • 6.2.3. By End-Use Industry
  • 6.2.4. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Preclinical CRO Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Service
      • 6.3.1.2.2. By Model Type
      • 6.3.1.2.3. By End-Use Industry
  • 6.3.2. Canada Preclinical CRO Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Service
      • 6.3.2.2.2. By Model Type
      • 6.3.2.2.3. By End-Use Industry
  • 6.3.3. Mexico Preclinical CRO Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Service
      • 6.3.3.2.2. By Model Type
      • 6.3.3.2.3. By End-Use Industry

7. Europe Preclinical CRO Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Service
  • 7.2.2. By Model Type
  • 7.2.3. By End-Use Industry
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Preclinical CRO Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Service
      • 7.3.1.2.2. By Model Type
      • 7.3.1.2.3. By End-Use Industry
  • 7.3.2. France Preclinical CRO Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Service
      • 7.3.2.2.2. By Model Type
      • 7.3.2.2.3. By End-Use Industry
  • 7.3.3. United Kingdom Preclinical CRO Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Service
      • 7.3.3.2.2. By Model Type
      • 7.3.3.2.3. By End-Use Industry
  • 7.3.4. Italy Preclinical CRO Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Service
      • 7.3.4.2.2. By Model Type
      • 7.3.4.2.3. By End-Use Industry
  • 7.3.5. Spain Preclinical CRO Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Service
      • 7.3.5.2.2. By Model Type
      • 7.3.5.2.3. By End-Use Industry

8. Asia Pacific Preclinical CRO Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Service
  • 8.2.2. By Model Type
  • 8.2.3. By End-Use Industry
  • 8.2.4. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Preclinical CRO Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Service
      • 8.3.1.2.2. By Model Type
      • 8.3.1.2.3. By End-Use Industry
  • 8.3.2. India Preclinical CRO Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Service
      • 8.3.2.2.2. By Model Type
      • 8.3.2.2.3. By End-Use Industry
  • 8.3.3. Japan Preclinical CRO Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Service
      • 8.3.3.2.2. By Model Type
      • 8.3.3.2.3. By End-Use Industry
  • 8.3.4. South Korea Preclinical CRO Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Service
      • 8.3.4.2.2. By Model Type
      • 8.3.4.2.3. By End-Use Industry
  • 8.3.5. Australia Preclinical CRO Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Service
      • 8.3.5.2.2. By Model Type
      • 8.3.5.2.3. By End-Use Industry

9. Middle East & Africa Preclinical CRO Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Service
  • 9.2.2. By Model Type
  • 9.2.3. By End-Use Industry
  • 9.2.4. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Preclinical CRO Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Service
      • 9.3.1.2.2. By Model Type
      • 9.3.1.2.3. By End-Use Industry
  • 9.3.2. UAE Preclinical CRO Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Service
      • 9.3.2.2.2. By Model Type
      • 9.3.2.2.3. By End-Use Industry
  • 9.3.3. South Africa Preclinical CRO Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Service
      • 9.3.3.2.2. By Model Type
      • 9.3.3.2.3. By End-Use Industry

10. South America Preclinical CRO Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Service
  • 10.2.2. By Model Type
  • 10.2.3. By End-Use Industry
  • 10.2.4. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Preclinical CRO Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Service
      • 10.3.1.2.2. By Model Type
      • 10.3.1.2.3. By End-Use Industry
  • 10.3.2. Colombia Preclinical CRO Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Service
      • 10.3.2.2.2. By Model Type
      • 10.3.2.2.3. By End-Use Industry
  • 10.3.3. Argentina Preclinical CRO Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Service
      • 10.3.3.2.2. By Model Type
      • 10.3.3.2.3. By End-Use Industry

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Preclinical CRO Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Eurofins Scientific SE
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. PRA Health Sciences, Inc.
• 15.3. Medpace, Inc.
• 15.4. Charles River Laboratories International, Inc.
• 15.5. PPD, Inc.
• 15.6. SGA SA
• 15.7. Intertek Group Plc
• 15.8. LABCORP Inc.
• 15.9. Crown Bioscience Inc

16. Strategic Recommendations

17. About Us & Disclaimer